Peptide-Modified Liposomes for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for coronary artery disease (CAD) and myocardial infarction (MI) face challenges in effectively targeting specific cell types in the infarct border zone, leading to systemic side effects and limited efficacy due to lack of specificity in drug delivery.
Innovation Solution
Development of liposomes with surface modifications using peptides specifically identified for cardiomyocytes, endothelial cells, myofibroblasts, and c-Kit+ cells in the infarct border zone, utilizing in vivo phage display methods and fluorescence molecular tomography (FMT) for targeted delivery of therapeutic agents like PARP-1 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic therapy is used to treat cell types in the infarct border zone, then therapeutic coverage is achieved, but specificity to target cells is reduced and systemic side effects occur
Solution Approach 1:
The patent applies local quality by modifying liposomes with cell-type-specific peptides (I-1 for cardiomyocytes, B-40 for endothelial cells, B-29 for myofibroblasts, B-50 for c-Kit+ cells) that enable targeted delivery to specific cell types in the infarct border zone. This allows the therapeutic effect to be localized to the intended target cells while minimizing exposure to other tissues, thereby resolving the contradiction between achieving therapeutic coverage and avoiding systemic side effects.
2Quantity of substance
If free drug formulations are used, then drug availability is achieved, but targeting precision to specific cell types is lost
Solution Approach 1:
The patent uses liposomes as intermediary carriers that can simultaneously provide drug delivery (maintaining drug availability) and targeted positioning (achieving targeting precision). The liposomes are conjugated with specific peptides that act as mediators to guide the drug to particular cell types, thus resolving the contradiction between maintaining drug availability and achieving targeting precision.
3Ease of operation
If non-specific drug delivery is used, then administration simplicity is maintained, but therapeutic efficiency at the target site is reduced
Solution Approach 1:
The patent creates a universal liposomal delivery platform that can be adapted to target multiple different cell types by simply changing the peptide conjugate (I-1, B-40, B-29, or B-50). This multi-functional system maintains the simplicity of intravenous administration while significantly improving therapeutic efficiency through targeted delivery, thus resolving the contradiction between administration simplicity and therapeutic efficiency.
Data Source
AI summary
Isolated peptides targeting cardiovascular disease are described herein or one or more conservative amino acid substitutions, deletions or additions of such peptides and methods of use thereof for delivering payloads to specific cell types or tissues.